title: Synthesis and anti-hyperlipidemic evaluation of N‑(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats.
abstract: The lipid-lowering activity of a series of novel N-(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives has been studied in Triton WR-1339-induced hyperlipidemia in rats. The test animals were divided into four groups: control, hyperlipidemic, compound + 4% DMSO [C1: N-(2-benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide (1), C2: N-(3-benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide (2), C3: N-(4-benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide (3)]-treated and bezafibrate (BF)-treated. At a dose of 15 mg/Kg body weight, compounds 2, 3 and BF significantly reduced elevated plasma triglycerodes levels after 12 h. Moreover, high density lipoprotein-cholesterol levels were significantly increased in all treated groups after 12 h compared to the hyperlipidemic control group, except for C1 which was inactive. In sum, it may be stated that the results of the present study demonstrated new properties of some N-(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives as potent lipid lowering agents and these beneficial activities may contribute to their cardioprotective and antiatherosclerotic role.
authors.affiliation: Faculty of Pharmacy, Al-Zaytoonah Private University, Amman, Jordan. gassan10@yahoo.com
authors.forename: Ghassan
authors.initials: G
authors.lastname: Shattat
authors.forename: Rania
authors.initials: R
authors.lastname: Al-Qirim
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Al-Hiari
authors.forename: Ghassan Abu
authors.initials: GA
authors.lastname: Sheikha
authors.forename: Tariq
authors.initials: T
authors.lastname: Al-Qirim
authors.forename: Waseem
authors.initials: W
authors.lastname: El-Huneidi
authors.forename: Moyad
authors.initials: M
authors.lastname: Shahwan
mesh_terms: D000818:Animals; D001629:Bezafibrate / Q000494:pharmacology / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use; D007211:Indoles / Q000138:chemical synthesis* / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D011092:Polyethylene Glycols / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013329:Structure-Activity Relationship
chemical_list: D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D007211:Indoles; C558484:N-(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide; D011092:Polyethylene Glycols; C016811:tyloxapol; D001629:Bezafibrate